Safety and efficacy of omalizumab for antihistamine-resistant chronic urticaria in children: a case series and literature review

Psychiatric comorbidities in children and adolescents with chronic urticaria

(2022) George N. Konstantinou et al.   World Journal of Pediatrics

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China

(2022) Ao Wang et al.   World Allergy Organization Journal

The International EAACI/GA²LEN/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis and Management of Urticaria

(2021) T. Zuberbier et al.   ALLERGY

Expert consensus on the use of omalizumab in chronic urticaria in China

(2021) Zuotao Zhao et al.   World Allergy Organization Journal

Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature

(2020) Stefano Passanisi et al.   Dermatologic Therapy

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria ‐ a systematic review for the EAACI Biologicals Guidelines

(2020) Ioana Agache et al.   ALLERGY

Severe chronic spontaneous urticaria in children – treatment options according to the guidelines and beyond – a 10 years review

(2020) Petra Staubach et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and tolerability of the updosing of second‐generation non‐sedating H1 antihistamines in children with chronic spontaneous urticaria

(2020) Lucrezia Sarti et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

The global burden of chronic urticaria for the patient and society

(2020) M. Gonçalo et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi‐center retrospective case series

(2020) Anne Ari et al.   PEDIATRIC DERMATOLOGY

Evaluating the efficacy of omalizumab therapy in a group of adolescents with chronic urticaria in real clinical practice

(2020) Vera Kalugina et al.   World Allergy Organization Journal

Omalizumab in children and adolescents with chronic urticaria: A 16‐week real‐world study

(2020) Xiao‐ting Song et al.   ALLERGY

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

(2020) Coco Dekkers et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

Management of Chronic Urticaria in a Pediatric Population

(2019) Sofianne Gabrielli et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Omalizumab for Chronic Urticaria in Children Less than 12 Years of Age: A Systematic Review.

(2019) Taha Al-Shaikhly et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta‐analysis

(2019) Julia Fricke et al.   ALLERGY

Omalizumab for management of chronic urticaria in a pediatric population: a case-series

(2018) Jason El Bilali et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety

(2017) Ana M Giménez-Arnau   EXPERT OPINION ON BIOLOGICAL THERAPY

How Often are Pediatric Patients with Clinically Amyopathic Dermatomyositis Truly Amyopathic?

(2016) Edward J. Oberle et al.   PEDIATRIC DERMATOLOGY

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

(2013) Marcus Maurer et al.   NEW ENGLAND JOURNAL OF MEDICINE